Chromium supplementation enhances insulin signalling in skeletal muscle of obese KK/HlJ diabetic mice

Diabetes, Obesity and Metabolism

Volumn 11, Issue 4, 2009, Pages 293-303

  Chen, W Y ^a   Chen, C J ^b   Liu, C H ^a   Mao, Frank Chiahung ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Chromium; Inflammation; Insulin resistance; JNK

Indexed keywords

CHROMIUM; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; STRESS ACTIVATED PROTEIN KINASE; AUTACOID; CYTOKINE; GLUCOSE BLOOD LEVEL; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN PHOSPHORYLATION; SKELETAL MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BIOSYNTHESIS; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG SCREENING; GLUCOSE TOLERANCE TEST; INBRED MOUSE STRAIN; LIPID METABOLISM; METABOLISM; MILK; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; WEIGHT GAIN;

ANIMALS; BLOOD GLUCOSE; CHROMIUM; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DRUG EVALUATION, PRECLINICAL; GLUCOSE TOLERANCE TEST; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MICE; MICE, INBRED STRAINS; MILK; MUSCLE, SKELETAL; OBESITY; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TRIGLYCERIDES; WEIGHT GAIN;

EID: 61549107267     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00936.x     Document Type: Article

References (49)

1. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Investig 2000; 106: 453-458.
2. King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care 1998; 21: 1414-1431.
3. Boyne MS, Saudek CD. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes. Diabetes Care 1999; 22: C45-C53.
4. Lebovitz HE. Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes. Diabetes Care 1999; 22: C41-C44.
5. Stump CS, Henriksen EJ, Wei Y, Sowers JR. The metabolic syndrome: Role of skeletal muscle metabolism. Ann Med 2006; 38: 389-402.
6. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
7. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481.
8. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with insulin receptor and inhibits insulin action. J Biol Chem 2002; 277: 1531-1537.
9. Hirosumi J, Tuncman G, Chang L et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-336.
10. Lee YH, Giraud J, Davis RJ, White MF. C-Jun N-terminal Kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 2003; 278: 2896-2902.
11. Anderson RA. Chromium, glucose intolerance and diabetes. J Am Coll Nutr 1998; 17: 548-555.
12. Ding W, Chai Z, Duan P, Feng W, Qian Q. Serum and urine chromium concentrations in elderly diabetics. Biol Trace Elem Res 1998; 63: 231-237.
13. Ekmekcioglu C, Prohaska C, Pomazal K, Steffan I, Schernthaner G, Marktl W. Concentrations of seven trace elements in different hematological matrices in patients with type 2 diabetes compared to healthy controls. Biol Trace Elem Res 2001; 79: 205-219.
14. Anderson RA, Polansky MM, Bryden NA, Canary JJ. Supplemental chromium effects on glucose, insulin, glucagon and urinary loss in subjects consuming low-chromium diets. Am J Cardiovasc Drugs 1991; 54: 909-916.
15. Anderson RA, Polansky MM, Bryden NA, Canary JJ. Effects of supplemental chromium on patients with symptoms of reactive hypoglycemia. Metabolism 1987; 36: 351-355.
16. Wang ZQ, Zhang XH, Russell JC, Hulver M, Cefalu WT. Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR: LA-cp rats. J Nutr 2006; 136: 415-420.
17. Yang X, Palanichamy K, Ontko AC et al. A newly synthetic chromium complex chromium (phenylalanine)3 improves insulin responsiveness and reduces whole body glucose tolerance. FEBS Lett 2005; 579: 1458-1464.
18. Chen G, Liu P, Pattar GR et al. Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol Endocrinol 2006; 20: 857-870.
19. Pei D, Hsieh CH, Hung YJ, Li JC, Lee CH, Kuo SW. The influence of chromium chloride-containing milk on glycemic control of patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial. Metabolism 2006; 55: 923-927.
20. Nakamura T, Yamada K. Studies on a diabetic (KK) strain of mice. Diabetologia 1967; 3: 212-221.
21. Suto J, Matsuura S, Imamura K, Yamanaka H, Sekikawa K. Genetic analysis of non-insulin-dependent diabetes mellitus in KK and KK-Ay mice. Eur J Endocrinol 1998; 139: 654-661.
22. Gunton JE, Hams G, Hitchman R, McElduff A. Serum chromium does not predict glucose tolerance in late pregnancy. Am J Clin Nutr 2001; 73: 99-104.
23. Polotsky VY, Li J, Punjabi NM et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol 2003; 552 (Pt 1) 253-264.
24. Cao XP, Xiao HP, Chen SJ, Zhan YF, Xiu LL, Wang ZL. Beta-cell dysfunction is the primary contributor to the early postpartum diabetes among Chinese women with history of gestational diabetes mellitus. Chin Med J 2008; 121: 696-700.
25. Liao SL, Ou YC, Chen SY, Chiang AN, Chen CJ. Induction of cyclooxygenase-2 expression by manganese in cultured astrocytes. Neurochem Int 2007; 50: 905-915.
26. Bodary PF, Vargas FB, King SAD, Jongeward KL, Wickenheiser KJ. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. J Thromb Haem 2005; 3: 2149-2153.
27. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119.
28. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
29. Lukaski HC. Chromium as a supplement. Annu Rev Nutr 1999; 19: 279-302.
30. DeFronzo RA, Jacot E, Jequier E. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 1981; 30: 1000-1007.
31. Wei Y, Chen K, Whaley-Connell AT, Stump CS, Ibdah JA, Sowers JR. Skeletal muscle insulin resistance: Role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Physiol 2008; 294: R673-R680.
32. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser (307). J Biol Chem 2000; 275: 9047-9054.
33. Weston CR, Lambright DG, Davis RJ. Signal transduction. MAP kinase signaling specificity. Science 2002; 296: 2345-2347.
34. Andreozzi F, Laratta E, Procopio C et al. Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells. Mol Cell Biol 2007; 27: 2372-2383.
35. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745-E751.
36. Kohn LD, Wallace B, Schwartz F, McCall K. Is type 2 diabetes an autoimmune-inflammatory disorder of the innate immune system? Endocrinology 2005; 146: 4189-4191.
37. Andreozzi F, Laratta E, Cardellini M et al. Plasma interleukin-6 levels are independently associated with insulin secretion in a cohort of Italian-Caucasian nondiabetic subjects. Diabetes 2006; 55: 2021-2024.
38. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
39. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
40. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF-alpha by human muscle. Relationship to insulin resistance. J Clin Invest 1996; 97: 1111-1116.
41. Rui L, Aguirre V, Kim JK et al. Insulin/IGF-1 and TNF stimulate phosphorylation of IRS1 at inhibitory Ser307 via distinct pathways. J Clin Invest 2001; 107: 181-189.
42. Rader DJ. Inflammatory markers of coronary risk. N Engl J Med 2000; 343: 1179-1182.
43. Singh U, Devraj S, Jialal I. Vitamin E, oxidative stress and inflammation. Annu Rev Nutr 2005; 25: 151-174.
44. Cavallo MG, Pozzilli P, Bird C et al. Cytokines in sera from insulin-dependent diabetic patients at diagnosis. Clin Exp Immunol 1991; 86: 256-259.
45. Kaneto H, Nakatani Y, Miyatsuka T et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 2004; 53: 1060-1067.
46. Weigert C, Hennige AM, Lehmann R et al. Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem 2006; 281: 7060-7067.
47. Jain SK, Rains JL, Croad JL. Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNF-α, IL-6, CRP, glycated hemoglobin, triglycerides, and cholesterol levels in blood of streptozotocin-treated diabetic rats. Free Radic Biol Med 2007; 43: 1124-1131.
48. Abraham AS, Brooks BA, Eylath U. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. Metabolism 1992; 41: 768-771.
49. Mahdi GS. Chromium deficiency might contribute to insulin resistance, type 2 diabetes, dyslipidemia and atherosclerosis. Diabet Med 1996; 13: 389-391.